ISDA

Entry Detail

PDB ID:

6ZIS

Keywords:

MEMBRANE PROTEIN

Title:

Crystal structure of a CGRP receptor ectodomain heterodimer with bound high affinity inhibitor

Biological Source:

Source Organism:

Escherichia coli (strain K12), Homo sapiens

Host Organism:

Homo sapiens

PDB Version:

Deposition Date:

2020-06-26

Release Date:

2020-07-15

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.73 Å

R-Value Free:

0.24

R-Value Work:

0.19

R-Value Observed:

0.20

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Maltose/maltodextrin-binding periplasmic protein,Receptor activity-modifying protein 1,Calcitonin gene-related peptide type 1 receptor
Chain IDs:A
Chain Length:594
Number of Molecules:1
Biological Source:Escherichia coli (strain K12), Homo sapiens

UniProt ID:A0A4P1LXE0 Pfam ID:PF01547

Ligand Molecules

3N6

PG4

Peptide-like Molecules

PRD_900001

Primary Citation

Structure-Based Drug Discovery ofN-((R)-3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(((S)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine.

Bucknell, S.J, Ator, M.A, Brown, A.J.H, Brown, J, Cansfield, A.D, Cansfield, J.E, Christopher, J.A, Congreve, M, Cseke, G, Deflorian, F, Jones, C.R, Mason, J.S, O'Brien, M.A, Ott, G.R, Pickworth, M, Southall, S.M.Show

J.Med.Chem. 63 7906 7920 (2020)

PMID: 32558564 DOI: 10.1021/acs.jmedchem.0c01003

Abstact

Structure-based drug design enabled the discovery of 8, HTL22562, a calcitonin gene-related peptide (CGRP) receptor antagonist. The structure of 8 complexed with the CGRP receptor was determined at a 1.6 Å resolution. Compound 8 is a highly potent, selective, metabolically stable, and soluble compound suitable for a range of administration routes that have the potential to provide rapid systemic exposures with resultant high levels of receptor coverage (e.g., subcutaneous). The low lipophilicity coupled with a low anticipated clinically efficacious plasma exposure for migraine also suggests a reduced potential for hepatotoxicity. These properties have led to 8 being selected as a clinical candidate for acute treatment of migraine.

Legend

Protein

Chemical

Disease

Primary Citation of related structures